Ltr Pharma Fpo has released a press release.
Appendix 4D and Half Yearly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from LTR Pharma
- SPONTAN Shows Positive Outcomes in Younger Men with ED
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patients Dosed in SPONTAN Phase II Clinical Study
- TGA Provides Regulatory Clearance for SPONTAN Phase II
- Ethics Approval Received for SPONTAN Phase II Clinical Study
Later from LTR Pharma
- SPONTAN Phase II Clinical Study Completes Recruitment
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- LTR Secures First U.S. Commercial Agreement for ROXUS
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma